<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04910165</url>
  </required_header>
  <id_info>
    <org_study_id>SLIR 2019-106</org_study_id>
    <nct_id>NCT04910165</nct_id>
  </id_info>
  <brief_title>Exparel Use in Adductor Canal Block After Total Knee Arthroplasty</brief_title>
  <official_title>Adductor Canal Blocks Using Exparel for Pain Control After Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's Hospital, Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Luke's Hospital, Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exparel has been shown to have better pain control compared to previously used infiltration&#xD;
      agents, including bupivacaine, while having a minor side effect profile. The purpose of this&#xD;
      study is to explore the effectiveness of Exparel (liposomal bupivacaine) in Adductor Canal&#xD;
      Blocks for peri-operative pain control following a total knee arthroplasty (TKA) procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effectiveness of an Exparel Block (Bupivacaine Liposomal Injectable Suspension) for&#xD;
      post-operative pain control has been well studied with encouraging results. At the&#xD;
      investigators' institution, Exparel has been approved as a safe and effective option for use&#xD;
      in shoulder surgeries and have had encouraging results in adductor canal use for pain control&#xD;
      in patients undergoing TKA. Exparel has been shown to have better pain control compared to&#xD;
      previously used infiltration agents, including bupivacaine, while having a minor side effect&#xD;
      profile. The purpose of this study is to explore the effectiveness of Exparel (liposomal&#xD;
      bupivacaine) in Adductor Canal Blocks (ACB) for peri-operative pain control following a total&#xD;
      knee arthroplasty (TKA) procedure. Specifically, the investigators look to see if Exparel ACB&#xD;
      reduces opioid requirement use post-operatively, reduces pain scores post-operatively,&#xD;
      provides earlier mobilization, and decreases length of hospital stay.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Actual">September 15, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>Through entire inpatient hospital stay, usually less than 1 week</time_frame>
    <description>Measured in hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid Use</measure>
    <time_frame>6 weeks</time_frame>
    <description>Inpatient and Outpatient use as measured in Millimorphine Equivalents</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain score</measure>
    <time_frame>6 weeks</time_frame>
    <description>Measured with Numerical Rating Scale (Range: 0-10, Minimum:0, Maximum:10)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WOMAC Score</measure>
    <time_frame>6 weeks</time_frame>
    <description>Western Ontario and McMaster Universities Osteoarthritis Index Patient Subjective Outcome Score (Range: 0-96, Minimum:0, Maximum:96). Subsections include Pain (Range:0-20, Minimum:0, Maximum:20), Stiffness (Range:0-8; Minimum:0, Maximum:8), and Functional Limitation (Range0-68, Minimum:0, Maximum:68)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Arthritis Knee</condition>
  <condition>Pain, Postoperative</condition>
  <condition>Opioid Use</condition>
  <arm_group>
    <arm_group_label>Exparel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposomal Bupivacaine use as active ingredient in the block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ropivacaine use as active ingredient in the block</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel</intervention_name>
    <description>Exparel used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine</description>
    <arm_group_label>Exparel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Ropivacaine used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients were eligible for inclusion if they were undergoing unilateral primary TKA&#xD;
             for a diagnosis of knee osteoarthritis and were not undergoing any additional&#xD;
             concomitant procedures were.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients were not eligible for our study if they were undergoing revision TKA, if they&#xD;
             were undergoing bilateral TKA or concomitant procedures, or if they had an active&#xD;
             infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chinenye Nwachuku, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's Hospital and Health Network, Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ajith Malige, MD</last_name>
    <phone>4084066595</phone>
    <email>ajith.malige@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chinenye Nwachuku, MD</last_name>
    <email>chinenye.nwachuku@sluhn.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Luke's University Health Network</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ajith Malige, MD</last_name>
      <phone>408-406-6595</phone>
      <email>ajith.malige@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Chinenye Nwachuku, MD</last_name>
      <email>chinenye.nwachuku@sluhn.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Luke's Hospital, Pennsylvania</investigator_affiliation>
    <investigator_full_name>Chinenye Nwachuku</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Exparel</keyword>
  <keyword>adductor</keyword>
  <keyword>knee</keyword>
  <keyword>arthroplasty</keyword>
  <keyword>opioid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

